Boston Scientific Corp
BSX · NYSE · United States · Health Care · HC Equipment & Services
- Coverage
- FY2017–FY2026
- History
- 10 years
- Latest filing
- 10-Q · SEC EDGAR
- Reporting
- USD
- Fiscal year end
- December
- Last updated
- Aug 2026
Headline figures
Boston Scientific Corp at a glance
In FY2026, Boston Scientific Corp reported revenue of USD — mn, EBITDA of USD — mn, EBITDA margin of —.
| USD mn | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | 20,074 | — | |||
| EBITDA | 5,385 | — | |||
| EBITDA margin | 26.8% | — | |||
| Free cash flow | 3,658 | — | |||
| ROIC | 10.7% | — |
The full 10-year history, every line item and each formula are in the platform.
In the platform
- Stat Book — normalized and as-reported IS, BS and CF
- Up to 10 years of annual and quarterly history
- Peer benchmarking and the stock screener
- Corporate risk scorecard
- DCF model from the filed inputs
- Tearsheet and live Excel formulas